Regular use of fish oil supplements and course of cardiovascular diseases: prospective cohort study

Author:

Chen Ge,Qian Zhengmin (Min),Zhang Junguo,Zhang Shiyu,Zhang ZilongORCID,Vaughn Michael G,Aaron Hannah E,Wang Chuangshi,Lip Gregory YH,Lin HualiangORCID

Abstract

ObjectiveTo examine the effects of fish oil supplements on the clinical course of cardiovascular disease, from a healthy state to atrial fibrillation, major adverse cardiovascular events, and subsequently death.DesignProspective cohort study.SettingUK Biobank study, 1 January 2006 to 31 December 2010, with follow-up to 31 March 2021 (median follow-up 11.9 years).Participants415 737 participants, aged 40-69 years, enrolled in the UK Biobank study.Main outcome measuresIncident cases of atrial fibrillation, major adverse cardiovascular events, and death, identified by linkage to hospital inpatient records and death registries. Role of fish oil supplements in different progressive stages of cardiovascular diseases, from healthy status (primary stage), to atrial fibrillation (secondary stage), major adverse cardiovascular events (tertiary stage), and death (end stage).ResultsAmong 415 737 participants free of cardiovascular diseases, 18 367 patients with incident atrial fibrillation, 22 636 with major adverse cardiovascular events, and 22 140 deaths during follow-up were identified. Regular use of fish oil supplements had different roles in the transitions from healthy status to atrial fibrillation, to major adverse cardiovascular events, and then to death. For people without cardiovascular disease, hazard ratios were 1.13 (95% confidence interval 1.10 to 1.17) for the transition from healthy status to atrial fibrillation and 1.05 (1.00 to 1.11) from healthy status to stroke. For participants with a diagnosis of a known cardiovascular disease, regular use of fish oil supplements was beneficial for transitions from atrial fibrillation to major adverse cardiovascular events (hazard ratio 0.92, 0.87 to 0.98), atrial fibrillation to myocardial infarction (0.85, 0.76 to 0.96), and heart failure to death (0.91, 0.84 to 0.99).ConclusionsRegular use of fish oil supplements might be a risk factor for atrial fibrillation and stroke among the general population but could be beneficial for progression of cardiovascular disease from atrial fibrillation to major adverse cardiovascular events, and from atrial fibrillation to death. Further studies are needed to determine the precise mechanisms for the development and prognosis of cardiovascular disease events with regular use of fish oil supplements.

Funder

Bill & Melinda Gates Foundation

Publisher

BMJ

Reference43 articles.

1. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019

2. Association between stroke and subsequent risk of suicide: a systematic review and meta-analysis;Vyas;Stroke,2021

3. Cardiovascular effects of marine omega-3 fatty acids

4. National Institute for Health and Care Excellence . Guidelines. cardiovascular disease: risk assessment and reduction, including lipid modification. London National Institute for Health and Care Excellence (NICE); 2016. Available: https://www.nice.org.uk/guidance/ng238?UID=3279581122023122671124

5. 2021 Dietary Guidance to Improve Cardiovascular Health: A Scientific Statement From the American Heart Association

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3